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Abstract Ovarian cancer is the leading cause of death
due to gynecological cancer and the 5th cause of death for
cancer in women in Europe. Optimal management of
patients with ovarian cancer needs the participation of a
well-trained multidisciplinary team. In the last few years,
we have observed a significant improvement in the
knowledge of the molecular biology of the different his-
totypes of ovarian cancer that will probably change our
standard of care in the forthcoming years. In this Guideline,
we summarize the most current evidence for the medical
management of ovarian cancer.
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Introduction
Despite improvements in surgery and chemotherapy,
ovarian cancer is still the leading cause of death for
gynecological cancer [1]. Unfortunately, there are no
methods for early detection or prevention applicable to the
general population, and majority of patients will present
with advanced disease. For this reason, the only way to
improve the survival of patients with ovarian cancer is to
offer the patient the best therapeutic alternatives delivered
by well-trained and motivated multidisciplinary team. The
aim of this guideline is to summarize the current evidence
and to give evidence-based recommendations for clinical
practice.
Methodology
This Guideline is based in great part in the GEICO (Grupo
Espan˜ol de Investigacio´n en Ca´ncer de Ovario) Guideline
that was published in 2013 which has been revised and
adapted to the SEOM Guideline format. To assign a level
of evidence and a grade of recommendation to the different
statements of this treatment guideline, it was decided to use
the Infectious Diseases Society of America-US Public
Health Service Grading System for Ranking Recommen-
dations in Clinical Guidelines to determine the quality of
evidence and strength of recommendation in each of the
consensus recommendations (Table 1).
Pathology and molecular diagnosis
Epithelial ovarian cancer is no longer considered a single
disease, as it is composed of a diverse group of tumors
that can be classified based on distinctive morphologic
and molecular features [2]. Although we have not yet
different therapeutic approaches for the different subtypes,
they use to show a different natural behavior and prog-
nosis. Nevertheless, there is an increasing number of
clinical trials focused on specific subtypes (i.e. low-grade
serous ovarian cancer or clear cell carcinoma) or patients
with specific molecular alterations (i.e. patients with
BRCA or PI3K mutations). Due to the above mentioned
reasons, pathological classification of patients with epi-
thelial ovarian cancer according the WHO recommenda-
tions is mandatory nowadays. Specific immune-
histochemistry assays must be performed when required
in the differential diagnosis of a particular patient (II, A).
Table 2 summarizes the different subtypes and molecular
features.
A. Gonzalez-Martı´n (&)  I. Bover  J. M. Del Campo 
A. Redondo  L. Vidal
MD Anderson Cancer Center, Madrid, Spain
e-mail: agonzalezm@mdanderson.es
123
Clin Transl Oncol (2014) 16:1067–1071
DOI 10.1007/s12094-014-1229-z
Surgical treatment
Surgery is the cornerstone in staging and treatment of
ovarian cancer. Based on published improved outcomes, it
is recommended that a gynecologic oncologist surgeon
perform the primary surgery [II, A] [1].
Early disease (clinical stage I/II)
The aim is proper staging of disease and removal of all
macroscopic tumors. Surgery can be performed either by
laparotomy, which is the most accepted procedure, or
minimally invasive surgery in selected patients if per-
formed by an experienced gynecologic oncologist [II, A].
Procedures must comprise: thorough inspection and pal-
pation of all peritoneal surface, total hysterectomy and
bilateral salpingo-oophorectomy (TH ? BSO),
omentectomy, pelvic and bilateral aortic lymphadenectomy
up to the renal vessels, biopsies of pelvic peritoneum,
paracolic gutters and right infra diaphragmatic area, sam-
pling of ascites or peritoneal washing for cytology (when
no ascites is found) [3]. Appendectomy is recommended in
mucinous tumors. Under-staged patients in previous sur-
gery should be re-staged according to the same surgical
principles mentioned above. For a young patient
(\40 years) who wishes to maintain fertility, a unilateral
salpingo-oophorectomy may be adequate for selected stage
I tumors (Ia and Ic due to intraoperative rupture but with
negative cytology, grade 1 or 2, but not stage Ib) in addi-
tion to the staging procedure. After fulfilling their gesta-
tional desire, salpingo-oophorectomy and hysterectomy are
recommended [III, B] [4].
Advanced disease (III–IV)
The standard treatment of advanced OC is cytoreductive
surgery followed by platinum-based combination chemo-
therapy. Although the ultimate goal is cytoreduction to
microscopic disease by removing all visible disease [5, 6],
successful cytoreduction to small-volume disease (\1 cm)
increases the frequency of complete response and overall
survival [II, A]. According to the 4th Ovarian Cancer
Consensus Conference held in Vancouver, the term ‘‘opti-
mal’’ cytoreduction should be reserved for those with no
macroscopic residual disease [1]. Some contraindications
for the outcome of this ‘‘maximum’’ effort surgery have
been pointed out such as the following: poor performance
status, mesentery root involvement, extra-abdominal vis-
ceral disease, multiple intraparenchymal liver metastases,
or intestinal massive-serosal carcinomatosis [II, A].
Systemic therapy in first line
Early stages
Adjuvant platinum-based chemotherapy after surgery is
indicated in high-risk early stages (IA and IB Grade 3,





A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for
use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation
against use
E Good evidence to support a recommendation against
use
Quality of evidence
I Evidence from C1 properly randomized, controlled
trial
II Evidence from C1 well-designed clinical trial, without
randomization; from cohort or case-controlled
analytic studies (preferably from [1 center); from
multiple time series; or from dramatic results from
uncontrolled experiments
III Evidence from opinions of respected authorities,
based on clinical experience, descriptive studies, or
reports of expert committees
Table 2 Histological subtypes and markers
Subtype CK-7 CK-20 WT-1 P53 RE RP B-catenina Other/comments
High grade serous ? - ? ? ± ± BRCA germline-mutated (20 %)
Transitional is classified as high-grad e serous
with transitional features
Mucinous ? ± ; - - CDX2 variable
PAX8 (50 %)?
Endometrioid ? - ; ; ± ± ?(40–50 %)
Clear cell ? - - - -
Low-grade serous ? - ? ± ± MD Anderson two-tier grading system required
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clear cell tumors and any grade of stages IC and IIA) [I, A]
[7]. However, there is no consensus on the need to treat
stages IA/B Grade 2. Only low-risk patients (stages IA/B
Grade I) with correct surgical staging require observation
exclusively. The recommended regimen consists of at least
3 cycles of paclitaxel-carboplatin [I, A] [8].
Advanced stages
Conventional chemotherapy
According to the 4th Ovarian Cancer Consensus Confer-
ence the standard treatment should include paclitaxel
(175 mg/m2) and carboplatin (AUC 5–7.5) every 3 weeks
for six cycles [I, A] [1]. For patients not eligible to receive
a taxane (specifically paclitaxel), the combination of car-
boplatin and pegylated liposomal doxorubicin (PLD) could
be considered an alternative option [9].
Neoadjuvant chemotherapy (NAC)
The EORTC-55971 trial showed that in women with stage
IIIC or IV ovarian cancer, primary debulking surgery fol-
lowed by at least six cycles of platinum-based chemo-
therapy or three cycles of platinum-based NAC, followed
by interval debulking surgery, and then at least three more
cycles of platinum-based chemotherapy, achieved the same
OS (29 months PDS vs 30 months NAC) [10]. However,
some concerns have risen from the quality of the surgery
performed in this trial and the wide use of NAC even in
patients that would be candidate for optimal upfront deb-
ulking surgery [11]. In conclusion, NAC should be
reserved for those who cannot tolerate PDS and/or for
whom optimal cytoreduction is not feasible after an ade-
quate evaluation performed by a surgical team well trained
on cytoreduction [I, B].
Dose-dense regimen
A Japanese study evaluated the weekly (dose dense)
administration of paclitaxel in combination with carbo-
platin every 3 weeks in patients with advanced ovarian
cancer showing a benefit not only in PFS but also in OS
[12]. However, the MITO-7 trial has not confirmed the
dose-dense hypothesis with carboplatin and paclitaxel
administered in a weekly schedule. For this reason, at least
in Caucasian population dose dense cannot be consistently
recommended [I, B], although it could be an option
according to the 4th Ovarian Cancer Consensus
Conference.
Intraperitoneal chemotherapy (IP CT)
Three large randomized studies and one meta-analysis have
found improvements in PFS and OS when part of the
chemotherapy is administered directly in the peritoneal
cavity (Table 3) but with a significant increment in toxicity
[13–16]. Nevertheless, IP CT is shown to be unmistakably
superior to IV CT and is another standard option in the
management of patients with stage III and residual tumor
B1 cm after upfront surgery [I, A].
Antiangiogenic therapy
Based on the available data coming from 2 phase III
trials (GOG-218, ICON-7), bevacizumab added to initial
chemotherapy followed by a maintenance period should
be deserved for patients who, following standard sur-
gery, are found to have macroscopic residual disease [I,
A] [17, 18]. According to exploratory analysis, the
benefit seems to be more significant in patients with
either stage III disease and residual disease [1 cm, or
stage IV disease.
Table 3 Front line intraperitoneal studies











Cisplatin, 100 mg/m2 i.v.;
cyclophosphamide,
600 mg/m2 i.v.;
q 3 weeks 9 6
Cisplatin, 100 mg/m2 i.p.;
cyclophosphamide,










Cisplatin, 75 mg/m2 i.v.;
paclitaxel, 135 mg/m2 24-h
i.v.; q 3 weeks 9 6
Carboplatin, AUC 9 i.v.; q 28 days 9 2;
cisplatin, 100 mg/m2 i.p.; paclitaxel,










Cisplatin, 75 mg/m2 i.v.;
paclitaxel, 135 mg/m2 24-h
i.v.; q 3 weeks 9 6
Paclitaxel, 135 mg/m2 24-h i.v.; Cisplatin,
100 mg/m2 i.p.; paclitaxel, 60 mg/m2 i.p.






P = 0.05 P = 0.03
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Therapy for relapsed ovarian cancer
Approximately 70–80 % of patients diagnosed with EOC
will suffer a relapse after receiving first-line chemotherapy
based on platinum and taxane. Secondary cytoreduction
may be appropriate in selected patients despite there is no
level 1 evidence which demonstrates a survival advantage.
[II, B].
However, for the majority of patients with recurrent
EOC the treatment is based only on systemic therapy.
There is no survival benefit in the treatment of recurrent
OC with chemotherapy based exclusively on a rise in the
CA 125, and it anticipates a deterioration in the quality of
life [I, A] [19].
Relapsed patients are classified according to progres-
sion-free interval (PFI) in the following groups:
• Progression while receiving last line of platinum-based
therapy or within 4 weeks of last platinum dose.
• Progression-free interval since last line of platinum of
\6 months.
• Progression-free interval since last line of platinum of
6–12 months.
• Progression-free interval since last line of platinum of
[12 months.
Treatment of distinct subgroups defined by progression-
free interval
Treatment of patients with a PFI \6 months
In these patients non-platinum single-agent therapy with
paclitaxel, pegylated liposomal doxorubicin (PLD), topo-
tecan or gemcitabine is the best palliative option. These
drugs have shown response rates (RR) less than 20 % and
median overall survival (OS) of 9–12 months. [I, A]. The
addition of bevacizumab to standard monotherapy provides
statistically significant and clinically meaningful
improvement in PFS and objective RR [20].
Treatment of patients with a PFI [12 months
Patients with recurrent disease and a progression-free
interval over 12 months are considered fully platinum
sensitive, as they use to respond to retreatment with a
platinum-based regimen. We have strong evidence, sum-
marized in the Table 4, showing that a platinum-based
combination is associated to a longer PFS and also OS in
comparison to single-agent platinum chemotherapy [I, A]
[21–24]. As there is no combination that can be consid-
ered superior in terms of efficacy, the selection between
the different options should be based on the toxicity
profile of them. A randomized trial of bevacizumab
combined with carboplatin-gemcitabine and controlled
with placebo demonstrated a significant improvement in
PFS without any impact in OS. This regimen can be
considered one of the standard options in this population
[I, A] [25].
Treatment of patients with a PFI 6–12 months
Patients relapsing between 6 to 12 months after the last
platinum-based chemotherapy use to have lower response
to platinum and shorter PFS and OS. For this reason, dif-
ferent strategies beyond carboplatin-based regimens are
under investigation in this group of patients. One of these
strategies is the use of a non-platinum based regimen. A
subgroup analysis of a randomized trial comparing tra-
bectedin-PLD with PLD showed that those patients with a
PFI of 6–12 months at relapse obtained an increment in OS
when treated with trabectedin-PLD [26]. Based on this
result, this combination could be considered as an
Table 4 Randomized clinical trials in platinum-sensitive relapse
Study N Prior 6–12 Months*
(%)
Treatment PFS (m) HR 95 % CI OS
Taxane (%)
ICON 4 [21] 802 43 25 Carboplatin 9 0.76 0.66–0.89 24 m
Carboplatin-Pac 12 29 m*
GEICO 9801 [22] 81 87 42 Carboplatin 8.4 0.54 0.32–0.92 17 m
Carboplatin-Pac 12.2 –
AGO-EORTC [23] 356 70 40 Carboplatin 5.8 0.72 0.58–0.90 17.3 m*
Carboplatin-Gem 8.6 18 m
CALYPSO [24] 973 35 99 Carboplatin-Pac 9.4 0.821 0.72–0.94 33 m
Carboplatin-PLD 11.3 30.7 m
OCEANS [25] 484 100 42 Carboplatin-gemcitabine 8.4 0.48 0.38–0.60 35.2
Carboplatin-gemcitabine-bevacizumab 12.4 33.3
6–12 Months*: rate of patients with a PFI of 6–12 months; * P \ 0.05
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alternative to platinum-based regimen in this clinical set-
ting [II, A].
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